Rare loss-of-function mutations of PTGIR are enriched in fibromuscular dysplasia

Affiliation auteurs!!!! Error affiliation !!!!
TitreRare loss-of-function mutations of PTGIR are enriched in fibromuscular dysplasia
Type de publicationJournal Article
Year of Publication2021
AuteursGeorges A, Albuisson J, Berrandou T, Dupre D, Lorthioir A, D'Escamard V, Di Narzo AF, Kadian-Dodov D, Olin JW, Warchol-Celinska E, Prejbisz A, Januszewicz A, Bruneval P, Baranowska AA, Webb TR, Hamby SE, Samani NJ, Adlam D, Fendrikova-Mahlay N, Hazen S, Wang Y, Yang M-L, Hunker K, Combaret N, Motreff P, Chedid A, Fiquet B, Plouin P-F, Mousseaux E, Azarine A, Amar L, Azizi M, Gornik HL, Ganesh SK, Kovacic JC, Jeunemaitre X, Bouatia-Naji N
JournalCARDIOVASCULAR RESEARCH
Volume117
Pagination1154-1165
Date PublishedAPR 1
Type of ArticleArticle
ISSN0008-6363
Mots-clésFibromuscular dysplasia, Prostacyclin signalling, Rare loss-of-function variants, Spontaneous coronary artery dissection
Résumé

Aims Fibromuscular dysplasia (FMD) and spontaneous coronary artery dissection (SCAD) are related, non-atherosclerotic arterial diseases mainly affecting middle-aged women. Little is known about their physiopathological mechanisms. We aimed to identify rare genetic causes to elucidate molecular mechanisms implicated in FMD and SCAD. Methods and results We analysed 29 exomes that included familial and sporadic FMD. We identified one rare toss-of-function variant LoF) (frequency(gnomAD) = 0.000075) shared by two FMD sisters in the prostaglandin 12 receptor gene (PTGIR), a key player in vascular remodelling. Follow-up was conducted by targeted or Sanger sequencing (1071 FMD and 363 SCAD patients) or lookups in exome (264 FMD) or genome sequences (480 SCAD), all independent and unrelated. It revealed four additional LoF allele carriers, in addition to several rare missense variants, among FMD patients, and two LoF allele carriers among SCAD patients, including one carrying a rare splicing mutation (c.768 + 1C>G). We used burden test to test for enrichment in patients compared to gnomAD controls, which detected a putative enrichment in FMD (P-TRAPD = 8 x 10(4)), but not a significant enrichment (P-TRAPD = 0.12) in SCAD. The biological effects of variants on human prostaclycin receptor (hIP) signalling and protein expression were characterized using transient overexpression in human cells. We confirmed the LoFs (Q163X and P17RfsX6) and one missense (L67P), identified in one FMD and one SCAD patient, to severely impair hIP function in vitro. Conclusions Our study shows that rare genetic mutations in PTGIR are enriched among FMD patients and found in SCAD patients, suggesting a role for prostacyclin signalling in non-atherosclerotic stenosis and dissection. [GRAPHICS] .

DOI10.1093/cvr/cvaa161